Avadel Pharmaceuticals Plc
AVDL:NASDAQ
Avadel Pharmaceuticals is a branded specialty pharmaceutical company. The company's primary focus is on the development and potential FDA approval for FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, Avadel develops and markets a portfolio of sterile injectable drugs used in the hospital setting.
Streetwise Company Fact Sheet
© 2024 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
